ZVRA logo

ZVRA
Zevra Therapeutics Inc

23,985
Mkt Cap
$511.74M
Volume
421,802.00
52W High
$13.16
52W Low
$6.19
PE Ratio
14.41
ZVRA Fundamentals
Price
$8.93
Prev Close
$9.09
Open
$8.93
50D MA
$8.70
Beta
0.89
Avg. Volume
1.04M
EPS (Annual)
-$2.28
P/B
3.84
Rev/Employee
$400,203.39
$376.54
Loading...
Loading...
News
all
press releases
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Lags Revenue Estimates
Aclaris (ACRS) delivered earnings and revenue surprises of -9.59% and -33.04%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
More News
News Placeholder
Ironwood Pharmaceuticals (IRWD) Reports Q4 Loss, Lags Revenue Estimates
Ironwood (IRWD) delivered earnings and revenue surprises of -150.00% and -9.62%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Average Rating of "Moderate Buy" from Analysts
Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight analysts that are currently covering the company, MarketBeat...
MarketBeat·3d ago
News Placeholder
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevras executive officers and whether investor...
Business Wire·9d ago
News Placeholder
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Update
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) was the target of a significant growth in short interest during the month of January. As of January 30th, there was short interest totaling...
MarketBeat·10d ago
News Placeholder
Timothy Sangiovanni Sells 3,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) SVP Timothy Sangiovanni sold 3,000 shares of the company's stock in a transaction dated Tuesday, February 3rd. The shares were sold at an...
MarketBeat·23d ago
News Placeholder
Neil Mcfarlane Sells 91,000 Shares of Zevra Therapeutics (NASDAQ:ZVRA) Stock
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) CEO Neil Mcfarlane sold 91,000 shares of the firm's stock in a transaction dated Monday, February 2nd. The stock was sold at an average price...
MarketBeat·25d ago
News Placeholder
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of "Moderate Buy" from Analysts
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are currently covering the stock, MarketBeat Ratings...
MarketBeat·28d ago
News Placeholder
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Down 32.5% in January
Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Get Free Report) saw a significant drop in short interest in January. As of January 15th, there was short interest totaling 3,991,736 shares, a drop of 32.5...
MarketBeat·28d ago
News Placeholder
Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% Higher - Here's What Happened
Zevra Therapeutics (NASDAQ:ZVRA) Trading 5.2% Higher - What's Next...
MarketBeat·1mo ago
<
1
2
...
>

Latest ZVRA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.